Undisclosed TROP2-TRACTr / Janux Therapeutics - LARVOL DELTA

Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (Businesswire) - "In the first half of 2022, Janux expects to submit an IND for its PSMA-TRACTr candidate, targeting prostate-specific membrane antigen (PSMA), for the treatment of metastatic castration-resistant prostate cancer (mCPRC)....In 2023, Janux expects to submit an IND application for its TROP2-TRACTr, targeting trophoblast cell surface antigen 2 (TROP2)."

IND • Genito-urinary Cancer • Oncology • Prostate Cancer

Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results (Businesswire) - "TRACTr product candidates advancing as planned: (i) In the first half of 2022, Janux expects to submit an Investigational New Drug (IND) application for its PSMA-TRACTr candidate, targeting prostate-specific membrane antigen (PSMA); (ii) In the second half of 2022, Janux expects to submit an IND application for its EGFR-TRACTr candidate, targeting epidermal growth factor receptor (EGFR); (iii) In 2023, Janux expects to submit an IND application for its TROP2-TRACTr, targeting trophoblast cell surface antigen 2 (TROP2)."

IND • Oncology